Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

References

• Aitken M. Global oncology trend report: a review of 2015 and outlook to 2020. Parsippany, USA: MS Health and the IMS Institute for Healthcare Informatics; 2016.
   Google Scholar
• Institute for Safe Medications Practices. List of high-alert medications in acute care settings. huntingdon valley. PA: ISMP; 2018. Available from: http://www.ismp.org/tools/highalertmedications.pdf.
   Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621.
   PubMed Web of Science ®Google Scholar
• Escudero-Vilaplana V, Ribed A, Romero-Jimenez RM, et al. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents. Eur J Cancer Care (Engl). 2017;26(3):e12463.
   Web of Science ®Google Scholar
• Morillo-Verdugo R, MÁ C-H, MLA R-C. A new definition and refocus of pharmaceutical care: the barbate document. Farm Hosp. 2020;44(4):158.
   PubMed Web of Science ®Google Scholar
• Ribed A, Escudero-Vilaplana V, Romero-Jimenez RM, et al. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opin Drug Saf. 2016;15(4):427–435.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Kwaan HC. Thrombotic and bleeding complications associated with chemotherapy. Semin Thromb Hemost. 2012;38(8):808–817.
   PubMed Web of Science ®Google Scholar
• Caas Y, Connor TH, Tabachnik A, et al. Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting. J Oncol Pharm Pract. 23(5): 350–378. 2017.
   PubMed Web of Science ®Google Scholar
• García-Miguel FJ, Peyró R, Mirón RMF. Valoración anestésica preoperatoria y preparación del paciente quirúrgico. Rev Esp Anestesiol Reanim. 2013;60:11–26.
   Google Scholar
• HPA G, Carreño DJA. Cardiovascular pre-anesthesia evaluation in oncological surgery. Rev Colomb Anestesiol. 2016;44:17–22.
   Google Scholar
• Lorusso R, Vizzardi E, Johnson DM, et al., Cardiac surgery in adult patients with remitted or active malignancies: a review of preoperative screening, surgical management and short- and long-term postoperative results. Eur J Cardiothorac Surg. 54(1): 10–18. 2018.
   PubMed Web of Science ®Google Scholar
• Zarazúa-Juárez M, Gómez-Sanchez G, García-Moranet EA. et al. Alto riesgo perioperatorio en el paciente oncológico sometido a cirugía no oncológica. Revista mexicana de anestesiología. 2016;39(1):S76–S78.
   Google Scholar
• European Public Assessment Reports. London: European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• FDA. Approved drug products. Silver Spring: U. S. Food and Drugs Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
   Google Scholar
• Fizazi K, NamPhuong T, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Bossi P, Menis J, et al. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol. 2018;29(4):985–991.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge R, Shaw T, et al. Alectinib versus crizotinib in untreated alk -positive non–small-cell lung cancer. N Engl J Med. 2017;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto P, Gogas H, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–605.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto P, Gogas H, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol. 2018;19(10):1315–1327.
   PubMed Web of Science ®Google Scholar
• Gurun Kaya A, Erol S, Ciledag A, et al. Dasatinib related pleural effusions with three cases. Am J Respir Crit Care Med. 2020;201:A6617.
   Google Scholar
• Yassin MA, Nashwan A, Kassem N. Second generation tyrosine kinase inhibitors as upfront therapy in the era of sleeve gastrostomy does it work? Blood. 2017;1:130.
   Google Scholar
• Cuéllar Obispo E, Alvaro Sanz E, Faus Felipe V, et al. Manejo perioperatorio de medicación crónica: documento de apoyo al PAI atención al paciente quirúrgico [Sevilla]. Consejería de Salud. 2015.
   Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010;116(24):5599–5607.
   PubMed Web of Science ®Google Scholar
• Hishida T, Nagai K, Mitsudomi T, et al. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg. 2010;140(5):e69–71.
   PubMed Web of Science ®Google Scholar
• Katayama T, Matsuo K, Kosaka T, et al. Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. Surg Oncol. 2010;19(4):e144–9.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Barabanshikova MV, Zubarovsky IN, Savarasov VM, et al. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12(3):140–145.
   PubMedGoogle Scholar
• Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood. 2019;34(1):22.
   Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Soon SL, Ibrahim SF, Arron ST, et al. Randomized phases II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. Br J Dermatol. 2019;181(1):208–209.
   PubMed Web of Science ®Google Scholar
• Matoses-Chirivella C, Navarro-Ruíz A, Lumbreras B. Development and validation of a guide for the continuity of care in perioperative medication management. J Orthop Traumatol. 2018;19(1):4.
   PubMed Web of Science ®Google Scholar
• López-Álvarez A, Román-Fernández MB. Chronic medications in the preoperative period: should they be stopped? Semergen. 2014;40(2):89–96.
   PubMedGoogle Scholar
• Osakidetza. Manejo de la medicación crónica en el perioperatorio. INFAC. Información farmacoterapéutica. 2017;25(9).
   Google Scholar
• Bailey CE, Parikh AA. Assessment of the risk of antiangiogenic agents before and after surgery. Cancer Treat Rev. 2018;68:38–46.
   PubMed Web of Science ®Google Scholar
• Harshman LC, Yu RJ, Allen GI. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013;31(3):379–385.
   PubMed Web of Science ®Google Scholar
• Sha DR, Dholakia S, Shah R. Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients. Drug Sat. 2014;37(3):135–149.
   PubMed Web of Science ®Google Scholar
• Tsunematsu M, Haruki K, Saito R, et al. Severe gastrointestinal hemorrhage related to everolimus: a case report. Clin J Gastroenterol. 2019;12(6):552–555.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–1239.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–2285.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757–1764.
   PubMed Web of Science ®Google Scholar
• Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441–464.
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist. 2005;10(1):72–79.
   PubMed Web of Science ®Google Scholar
• Yano R, Kurokawa T, Tsuyoshi H, et al. Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin. Ann Pharmacother. 2011;45(10):e55.
   PubMedGoogle Scholar
• Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005;5(3):175–180.
   PubMedGoogle Scholar
• Saif MW, Wasif N. Interaction between capecitabine and gemcitabine with warfarin a patient with pancreatic cancer. JOP. 2008;9:739–743.
   PubMedGoogle Scholar
• Arai S, Mitsufuji H, Nishii Y, et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol. 2009;14(4):332–336.
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao HP, Liu CX, et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev. 2007;39(4):699–721.
   PubMed Web of Science ®Google Scholar
• Streiff MB. Thrombosis in the setting of cancer. Hematol Am Soc Hematol Edu Prog. 2016;2016(1):196–205.
   PubMedGoogle Scholar
• Pachón Olmos VP, Ramos Gallo MJ, Rebollo MA, et al. Management of venous thromboembolism in oncological patients: spanish clinical practice guidelines. Consensus SEACV-SEOM. Med Clin (Barc). 2015;144(1):3–15.
   PubMedGoogle Scholar
• Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 141(2Suppl): e326S–50S. 2012.
   PubMed Web of Science ®Google Scholar
• The EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):e69–e71.
   Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al.; RE- MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–718.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al., Apixaban for the Treatment of venous Thromboembolism Associated with Cancer. N Engl J Med. 382(17): 1599–1607. 2020.
   PubMed Web of Science ®Google Scholar